cabozantinib
exelixis
['atlantis', 'urothelial', 'cabozantinib']
asco 2022 news: atlantis platform trial findings rule out the use of cabozantinib as maintenance therapy in patients with metastatic urothelial cancer.
Springer Healthcare IME, providing independent medical education in Neurology, Diabetes, Oncology, Rare Diseases, Endocrinology, and Paediatrics.